雷替曲塞为基础化疗方案治疗晚期原发性肝癌的临床观察
DOI: 10.3971/j.issn.1000-8578.2017.04.009
Keywords: A Case Report,Association Between Type-2 Diabetes Mellitus and Platelet Count in Patients with Primary Liver Cancers,Emergency Transcatheter Arterial Embolization Combined with Two-stage Liver Resection for Spontaneous Ruptured Hepatocellular Carcinoma: A Systematic Review,Therapeutic Effect of Raltitrexed or Fluorouracil plus Irinotecan as Second-line#br# Treatment for Advanced Colorectal Cancer,Microwave Ablation Combined with Stereotactic Radiotherapy for Primary and Recurrent Hepatocellular Carcinoma after Interventional Treatment,Clinical Efficacy of Raltitrexed Combined with Docetaxel for Advanced Gastric Cacinoma,Meta-analysis on Relationship between runx3 Gene and Hepatocellular Carcinoma,Clinical Effects of Yanshu on Primary Hepatic Carcinoma Treated with Interventional Therapy,Correlation of MMP-9 and MMP-2 Gene SNPs with Hepatocellular Carcinoma Invasion and Metastasis,Prevention and Treatment of Complications after Argon-helium Cryoablation on Primary Hepatocarcinoma,Percutaneous Microwave Coagultion Therapy Influence on Hepatofibrosis of Primary Hepatocellular Carcinoma Serum
Abstract:
摘要 目的 回顾性分析雷替曲赛为基础化疗方案治疗晚期原发性肝癌的疗效及安全性。方法 31 例原发性肝癌患者，均接受以雷替曲塞为基础方案化疗，其中二线治疗14例，三线及以上治疗17例，方案包括雷替曲塞联合伊立替康（TOMIRI）、雷替曲塞联合奥沙利铂（TOMOX）、雷替曲塞联合吉西他滨（TOMGEM）、雷替曲塞单药（RTX）。按照RECIST1.1版标准评价客观疗效，按照NCICTC 4.0版标准评价不良反应。结果 31例患者完成1周期以上的化疗，均可评价疗效，其中无完全和部分缓解患者，13例患者稳定（SD），18例患者进展（PD），有效率（RR）为0%，疾病控制率（DCR）为41.9%，中位TTP（mTTP）为63天，中位OS（mOS）为189天。常见的不良反应为骨髓抑制及消化道反应，多为Ⅰ~Ⅱ级，患者均可耐受。结论 雷替曲塞为基础化疗方案对标准治疗失败的晚期原发性肝癌仍有一定的疾病控制率，且安全性良好，值得进一步深入研究
Full-Text
